437 related articles for article (PubMed ID: 12102645)
1. Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1?
Holst JJ
BioDrugs; 2002; 16(3):175-81. PubMed ID: 12102645
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide-1 and control of insulin secretion.
Thorens B
Diabete Metab; 1995 Dec; 21(5):311-8. PubMed ID: 8586147
[TBL] [Abstract][Full Text] [Related]
3. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.
Vaag AA; Holst JJ; Vølund A; Beck-Nielsen HB
Eur J Endocrinol; 1996 Oct; 135(4):425-32. PubMed ID: 8921824
[TBL] [Abstract][Full Text] [Related]
4. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
Nauck MA; Heimesaat MM; Orskov C; Holst JJ; Ebert R; Creutzfeldt W
J Clin Invest; 1993 Jan; 91(1):301-7. PubMed ID: 8423228
[TBL] [Abstract][Full Text] [Related]
5. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.
Elahi D; McAloon-Dyke M; Fukagawa NK; Meneilly GS; Sclater AL; Minaker KL; Habener JF; Andersen DK
Regul Pept; 1994 Apr; 51(1):63-74. PubMed ID: 8036284
[TBL] [Abstract][Full Text] [Related]
6. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day.
Orskov C; Wettergren A; Holst JJ
Scand J Gastroenterol; 1996 Jul; 31(7):665-70. PubMed ID: 8819215
[TBL] [Abstract][Full Text] [Related]
7. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
[TBL] [Abstract][Full Text] [Related]
8. Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients.
Fukase N; Igarashi M; Takahashi H; Manaka H; Yamatani K; Daimon M; Tominaga M; Sasaki H
Diabet Med; 1993; 10(1):44-9. PubMed ID: 8435987
[TBL] [Abstract][Full Text] [Related]
9. Effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-I-(7-36) on insulin secretion.
Jia X; Brown JC; Ma P; Pederson RA; McIntosh CH
Am J Physiol; 1995 Apr; 268(4 Pt 1):E645-51. PubMed ID: 7733263
[TBL] [Abstract][Full Text] [Related]
10. Reduced insulinotropic effects of glucagonlike peptide I-(7-36)-amide and gastric inhibitory polypeptide in isolated perfused diabetic rat pancreas.
Suzuki S; Kawai K; Ohashi S; Mukai H; Murayama Y; Yamashita K
Diabetes; 1990 Nov; 39(11):1320-5. PubMed ID: 2146178
[TBL] [Abstract][Full Text] [Related]
11. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects.
Greenfield JR; Farooqi IS; Keogh JM; Henning E; Habib AM; Blackwood A; Reimann F; Holst JJ; Gribble FM
Am J Clin Nutr; 2009 Jan; 89(1):106-113. PubMed ID: 19056578
[TBL] [Abstract][Full Text] [Related]
12. Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Effect of sulfonylurea therapy.
Fukase N; Manaka H; Sugiyama K; Takahashi H; Igarashi M; Daimon M; Yamatani K; Tominaga M; Sasaki H
Acta Diabetol; 1995 Oct; 32(3):165-9. PubMed ID: 8590785
[TBL] [Abstract][Full Text] [Related]
13. The enteroinsular axis in dipeptidyl peptidase IV-negative rats.
Pederson RA; Kieffer TJ; Pauly R; Kofod H; Kwong J; McIntosh CH
Metabolism; 1996 Nov; 45(11):1335-41. PubMed ID: 8931636
[TBL] [Abstract][Full Text] [Related]
14. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells.
Moens K; Heimberg H; Flamez D; Huypens P; Quartier E; Ling Z; Pipeleers D; Gremlich S; Thorens B; Schuit F
Diabetes; 1996 Feb; 45(2):257-61. PubMed ID: 8549871
[TBL] [Abstract][Full Text] [Related]
15. The Insulin Response to Oral Glucose in GIP and GLP-1 Receptor Knockout Mice: Review of the Literature and Stepwise Glucose Dose Response Studies in Female Mice.
Ahrén B; Yamada Y; Seino Y
Front Endocrinol (Lausanne); 2021; 12():665537. PubMed ID: 34122340
[TBL] [Abstract][Full Text] [Related]
16. Molecular cloning, functional expression, and signal transduction of the GIP-receptor cloned from a human insulinoma.
Volz A; Göke R; Lankat-Buttgereit B; Fehmann HC; Bode HP; Göke B
FEBS Lett; 1995 Oct; 373(1):23-9. PubMed ID: 7589426
[TBL] [Abstract][Full Text] [Related]
17. GLP-1/GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1.
Gallwitz B; Witt M; Morys-Wortmann C; Fölsch UR; Schmidt WE
Regul Pept; 1996 May; 63(1):17-22. PubMed ID: 8795084
[TBL] [Abstract][Full Text] [Related]
18. Incretin hormone expression in the gut of diabetic mice and rats.
Berghöfer P; Peterson RG; Schneider K; Fehmann HC; Göke B
Metabolism; 1997 Mar; 46(3):261-7. PubMed ID: 9054467
[TBL] [Abstract][Full Text] [Related]
19. Insulinotropic effects of cholecystokinin, gastric inhibitory polypeptide and glucagon-like peptide-1 during perifusion of short-term cultured canine isolated islets.
van der Burg MP; Guicherit OR; Frölich M; Gooszen HG
Regul Pept; 1995 Dec; 60(1):61-7. PubMed ID: 8747785
[TBL] [Abstract][Full Text] [Related]
20. GIP and GLP-1(7-36)amide secretion in response to intraduodenal infusions of nutrients in pigs.
Knapper JM; Heath A; Fletcher JM; Morgan LM; Marks V
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol; 1995 Jul; 111(3):445-50. PubMed ID: 8564784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]